Reversal of T cell anergy in leprosy patients: In vitro presentation with Mycobacterium leprae antigens using murabutide and Trat peptide in liposomal delivery

International Immunopharmacology

Volumn 3, Issue 12, 2003, Pages 1589-1600

  Sridevi, K ^a   Khanna, Neena ^a   Chattree, Vineeta ^a   Pal, P C ^a   Haq, W ^b   Rao, D N ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Cytokines; Immunomodulators; Leprosy patients; Mycobacterial antigens; T cell anergy

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; MURABUTIDE; MYCOBACTERIUM ANTIGEN;

ANTIGEN PRESENTATION; ARTICLE; BORDERLINE LEPROSY; CELL STIMULATION; CELLULAR IMMUNITY; CLONAL ANERGY; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; IMMUNOMODULATION; LEPROMATOUS LEPROSY; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL;

EID: 0141637395     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(03)00181-4     Document Type: Article

References (32)

1. Ilangumaran S., Robinson P., Shankernarayan N.P., Ramu G., Mahadevan P.R.et al. T-lymphocyte reactivity of leprosy patients and healthy contacts from a leprosy-endemic population to delipidified cell components of Mycobacterium leprae. Lepr. Rev. 65:1994;34-44.
2. Nath I., Curtis J., Bhutani L.K., Talwar G.P. Reduction of a subpopulation of T lymphocytes in lepromatous leprosy. Clin. Exp. Immunol. 18:1974;81-87.
3. Bjune G. In vitro lymphocyte stimulation in leprosy; simultaneous stimulation with Mycobacterium leprae antigens and phytohaemagglutinin. Clin. Exp. Immunol. 36:1979;479-487.
4. Nath I., Curtis J., Sharma A.K., Talwar G.P. Circulating T cell numbers and their mitogenic potential in leprosy-correlation with mycobacterial load. Clin. Exp. Immunol. 29:1977;393-400.
5. Haregewoin A., Godal T., Mustafa A.S., Belehu A., Yemaneberhan T. T-cell conditioned media reverse T-cell unresponsiveness in lepromatous leprosy. Nature. 303:1983;342-344.
6. Zea A.H., Ochoa M.T., Ghosh P., Longo D.L., Alvord W.G., Valderrama L.et al. Changes in expression of signal transduction proteins in T lymphocytes of patients with leprosy. Infect. Immun. 66:1998;499-504.
7. Agrewala J.N., Kumar B., Vohra H. Potential role of B7-1 and CD28 molecules in immunosuppression in leprosy. Clin. Exp. Immunol. 111:1998;56-63.
8. Katia S., Uyemura K., Jullien D., Sieling P.A., Rea T.H.et al. B7-1, but not CD28, is crucial for the maintenance of the CD4+ T cell responses in human leprosy. J. Immunol. 161:1998;2407-2413.
9. Sharma N., Sharma V.K., Gupta A., Kaur I., Kaur S., Ganguly N.K. Alterations in early biochemical events following T cell activation in leprosy patients. Clin. Immunol. Immunopathol. 88:1998;142-149.
10. Majumdar V., Mukerjee A., Hajra S.K., Saha B., Saha K. Immunotherapy of far advanced lepromatous leprosy patients with low dose Convit vaccine along with multidrug therapy (Calcutta trial). Int. J. Lepr. 64:1996;26-36.
11. Mustafa A.S. Restoration of proliferative response to M. leprae antigens in lepromatous T cells against candidate anti-leprosy vaccines. Int. J. Lepr. Other Mycobact. Dis. 64:1996;257-267.
12. (a) Iyer R.R., Prasad H.K., Bhutani L.K., Rao D.N. Effect of tuftsin stimulation on the microbicidal activity exerted by blood monocyte-macrophage of leprosy patients. Int. J. Immunopharmacol. 12:1990;859-869;
13. (b) Iyer R.R., Prasad H.K., Bhutani L.K., Rao D.N. In vitro modulation of human lepromatous monocyte-macrophage functions by tuftsin. Int. J. Immunopharmacol. 12:1990;847-858.
14. Khare S., Bhutani L.K., Rao D.N. Quantitative assessment of tuftsin receptor expression and second messenger during in vitro differentiation of peripheral blood derived monocytes of leprosy patients. Mol. Cell. Biochem. 171:1997;1-10.
15. Verhagen C.E., Wierenga E.A., Buffing A.A., Chand M.A., Faber W.R., Das P.K. Reversal reaction in borderline leprosy is associated with a polarized shift to type 1-like Mycobacterium leprae T-cell reactivity in lesional skin: a follow-up study. J. Immunol. 159:1997;4474-4483.
16. Pouillart P.R., Audibert F.M., Chedid L.A., Lefrancier P.L., Bahr G.M. Enhancement by muramyl peptides of the protective response of interferon-alpha/beta against encephalomyocarditis virus infection. Int. J. Immunopharmacol. 18:1996;183-192.
17. Gregory JRJ, Sullivan JS, Geczy AF. Peptide sequences with strong stimulatory activity for lymphoid cells: implications for vaccine development 1993;11:1310-5.
18. Tindle R.W., Croft S., Herd K., Malcolm K., Geczy A.F., Stewart T.et al. A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants. Clin. Exp. Immunol. 101:1995;265-271.
19. Ridley D.S., Jopling W.H. Classification of leprosy according to immunity. A five-group system. Int. J. Lepr. 34:1966;255-273.
20. Turanek J., Toman M., Novak J., Krchnak V., Horavova P. Adjuvant effect of liposomes and adamantylamide dipeptide on antigenicity of entrapped synthetic peptide derived from HIV-1 transmembrane region glycoprotein gp41. Immunol. Lett. 39:1994;157-161.
21. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1g. Scand. J. Clin. Lab. Invest., Suppl. 97:1968;77-89.
22. Russell-Jones G.J., Sullivan J.S., Geczy A.F. Peptide sequences with strong stimulatory activity for lymphoid cells: implications for vaccine development. Vaccine. 11:1993;1310-1315.
23. Croft S., Walsh J., Lloyd W., Russell-Jones G.J. Trat; a powerful carrier molecule for the stimulation of immune responses to protein and peptide antigens. J. Immunol. 146:1991;793-798.
24. Heath T.D., Lopez N.G., Papahadjopoulos D. The effects of liposome size and surface charge on liposome-mediated delivery of methotrexate-γ -aspartate to cells in vitro. Biochim. Biophys. Acta. 820:1985;74-84.
25. Aramaki Y., Suda H., Tsuchiya S. Interferon-γ inductive effect of liposomes as an immunoadjuvant. Vaccine. 13:1995;1809-1814.
26. Britton W.J., Hellqvist L., Garsia R.J., Basten A. Dominant cell wall proteins of Mycobacterium leprae recognized by monoclonal antibodies. Clin. Exp. Immunol. 67:1987;31-42.
27. Mustafa A.S. M. leprae recombinant antigens important for T-cell reactivity. Indian J. Lepr. 7:1999;75-86.
28. Mohagheghpour N., Gelber R.R., Engleman E.G. T cell defect in lepromatous leprosy is reversible in vitro in the absence of exogenous growth factors. J. Immunol. 138:1987;570-574.
29. Al-Attiyah R.J., Bahr G.M., Strannegard O., Chedid L., Behbehani K. In vitro regulation of Muramyl dipeptide of interferon production from peripheral blood mononuclear cells of healthy volunteers. Int. J. Immunopharmacol. 10:1988;931-938.
30. SivaSai K.S.R., Prasad H.K., Misra R.S.et al. Effect of recombinant interferon gamma administration on lesional monocytes/macrophages in lepromatous patients. Int. J. Lepr. 61:1993;259-269.
31. Mosmann T.R., Sad S. The expanding universe of T cell subsets: Th1, Th2 and more. Immunol. Today. 17:1996;138-146.
32. Haregewoin A., Longley J., Bjune G., Mustafa A.S., Godal T. The role of interleukin-2 (IL-2) in the specific unresponsiveness of lepromatous leprosy to Mycobacterium leprae: studies in vitro and in vivo. Immunol. Lett. 11:1985;249-252.